Pharmaceutical preparation for treating demyelinating diseases of the nervous system; preparation promoting restoration of the myelin sheath of nerve fibers; and a method for treating demyelinating diseases of the nervous system

Abstract

The invention relates to a pharmaceutical remedy used to treat demyelinating diseases of the nervous system. The remedy contains stephaglabrin sulfate that contributes to the restoration of the myelin sheath of nerve fibers. A method for treating demyelinating diseases of the nervous system is also disclosed.

What is claimed is: 
     
         1 . A method of restoring myelin sheath of nerve fibers comprising administering to a subject in need of said restoring a pharmaceutical composition comprising 0.2 to 1.0% of stephaglabrin sulfate. 
     
     
         2 . The method of  claim 1 , wherein the pharmaceutical composition comprises 0.25% of stephaglabrin sulfate. 
     
     
         3 . The method as claimed in  claim 1 , wherein the pharmaceutical composition is administered twice a day. 
     
     
         4 . The method of  claim 1 , wherein the pharmaceutical composition is administered for 10-20 days. 
     
     
         5 . The method of  claim 1 , wherein the pharmaceutical composition is administered intramuscularly. 
     
     
         6 . The method of  claim 1 , wherein the pharmaceutical composition is administered parenterally. 
     
     
         7 . A method for treating a demyelinating disease of the nervous system in a subject comprising:
 administering to the subject a pharmaceutical composition comprising 0.2 to 1.0% of stephaglabrin sulfate;   administering a symptomatic therapy to the subject, and   administering an electrophysiological procedure to the subject,   
       wherein said pharmaceutical composition contributes to restoration of myelin sheath of nerve fibers in the subject. 
     
     
         8 . The method of  claim 7 , wherein the pharmaceutical composition comprises 0.25% of stephaglabrin sulfate. 
     
     
         9 . The method as claimed in  claim 7 , wherein the pharmaceutical composition is administered twice a day. 
     
     
         10 . The method of  claim 7 , wherein said demyelinating disease of the nervous system is selected from the group consisting of a lateral amyotrophyic syndrome, syringomyelia and amyotrophic lateral sclerosis. 
     
     
         11 . The method of  claim 7 , wherein the pharmaceutical composition is administered for 10-20 days. 
     
     
         12 . The method of  claim 7 , wherein the pharmaceutical composition is administered intramuscularly. 
     
     
         13 . The method of  claim 7 , wherein the pharmaceutical composition is administered parenterally.